title: A comparative study of T-cell depleted and non-depleted marrow transplantation for hematological malignancy.
abstract: Sixteen patients with hematological malignancy received cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 Gy), oral cyclosporin, and an HLA-identical sibling marrow transplant depleted of T cells by incubation with the monoclonal antibody anti-HuLy-m1 (CD2) and rabbit complement with (five patients) or without (11 patients) anti-HuLy-m8). These 16 patients were compared historically to 84 patients with hematological malignancy receiving cyclophosphamide (120 mg/kg), fractionated total body irradiation (12 or 14 Gy), oral cyclosporin, and unmanipulated HLA-identical sibling marrow, for parameters of engraftment and graft-versus-host disease (GVHD). Graft failure occurred in one of the 16 T-cell depleted recipients and in one of the 84 nondepleted recipients. Engraftment was slightly but significantly slower in the T-cell depleted group and bacterial infections significantly more frequent and severe than in the unmanipulated group. There was a suggestion that the severity of acute GVHD was reduced in those receiving T depleted marrow. Randomized trials will be necessary to determine if marrow T-cell depletion results in superior long-term leukemia-free survival.
authors.forename: K
authors.initials: K
authors.lastname: Atkinson
authors.forename: J
authors.initials: J
authors.lastname: Biggs
authors.forename: M
authors.initials: M
authors.lastname: Cooley
authors.forename: H
authors.initials: H
authors.lastname: Farrelly
authors.forename: E
authors.initials: E
authors.lastname: O'Flaherty
authors.forename: H
authors.initials: H
authors.lastname: Raphael
authors.forename: M
authors.initials: M
authors.lastname: Ashby
authors.forename: A
authors.initials: A
authors.lastname: Concannon
authors.forename: A
authors.initials: A
authors.lastname: Dodds
authors.forename: G
authors.initials: G
authors.lastname: Morgan
mesh_terms: D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy*; D008212:Lymphocyte Depletion; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D013601:T-Lymphocytes / Q000473:pathology; D014916:Whole-Body Irradiation
chemical_list: D007166:Immunosuppressive Agents